These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32421698)

  • 21. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
    Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
    J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
    Cheng KK
    Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia.
    Oosterom N; de Jonge R; Smith DEC; Pieters R; Tissing WJE; Fiocco M; van Zelst BD; van den Heuvel-Eibrink MM; Heil SG
    PLoS One; 2019; 14(9):e0221591. PubMed ID: 31527879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
    Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
    J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical evaluation of severe toxicity in two patients with acute lymphoblastic leukemia receiving outpatient methotrexate therapy].
    Hatae Y; Hatayama Y; Nishi M; Murakami T; Nobumoto K; Nakadate H; Iizuka S; Takeda T; Wada I
    Rinsho Ketsueki; 1991 Nov; 32(11):1503-8. PubMed ID: 1758061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of oral lesions in children with acute lymphoblastic leukemia.
    Pereira Pinto L; de Souza LB; Gordón-Núñez MA; Soares RC; de Brito Costa EM; de Aquino AR; Fernandes MZ
    Int J Pediatr Otorhinolaryngol; 2006 Nov; 70(11):1847-51. PubMed ID: 16914211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis.
    Schmidt E; Thoennissen NH; Rudat A; Bieker R; Schliemann C; Mesters RM; Zühlsdorf M; Müller-Tidow C; Berdel WE
    Ann Oncol; 2008 Sep; 19(9):1644-9. PubMed ID: 18453519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-Lipoic acid ameliorates oral mucositis and oxidative stress induced by methotrexate in rats. Histological and immunohistochemical study.
    Ahmed AA; Selim MA; El-Sayed NM
    Life Sci; 2017 Feb; 171():51-59. PubMed ID: 28062278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
    den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
    Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin's lymphoma of Waldeyer's ring.
    Eifel PJ; McClure S
    Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):907-8. PubMed ID: 2476427
    [No Abstract]   [Full Text] [Related]  

  • 36. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukemia.
    McKenna SJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Feb; 89(2):137-9. PubMed ID: 10673646
    [No Abstract]   [Full Text] [Related]  

  • 38. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
    Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Digestive disease in the immunocompromised patient with acute lymphoblastic leukemia. Experience of the IVth Pediatric Clinic--Oncology Department of the Iaşi Sfânta Maria Children's Hospital].
    Moisă SM; Rusu A; Dumitraş S; Burlea M; Miron I
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(2):356-65. PubMed ID: 19295004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
    Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
    J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.